Berberine, Chlorogenic Acid and Tocotrienols in Menopause-associated Dyslipidemia

IRCCS Policlinico S. Matteo

Status

Completed

Conditions

Dyslipidemia

Treatments

Other: Control

Dietary Supplement: Nutraceutical

Study type

Interventional

Funder types

Other

Identifiers

NCT03019263

20140012470

Details and patient eligibility

About

Menopause is usually associated with an increase in body weight, a change in body composition and fat distribution and a large number of cardio-metabolic changes, such as hypertension, reduction of insulin-sensitivity and dyslipidaemia. The first-line strategy for these complications is the modification of dietary habits and lifestyle in terms of physical activity. Besides, there is also a growing interest in complementary therapies (i.e. nutraceuticals) that can be used alone or in combination to achieve more consistent results. In this context, preliminary evidence supports the potential role of some compounds of vegetal origin such as berberine, chlorogenic acid and tocotrienols. However, in support of their use, the evidence from good quality trials is limited.

Enrollment

63 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

LDL cholesterol >100 mg/dL
Written informed consent available

Exclusion criteria

Use of any drug affecting blood lipids
Hormone replacement therapy
Adherence to a weigh loss diet in the previous 6 months
Cancer diagnosis
Known thyroid, liver, renal or muscle diseases
Any medical or surgical condition which could lead to an inconstant adhesion to the protocol